代谢功能障碍相关脂肪性肝炎临床试验中疑似药物性肝损伤因果关系评估的肝活检:肝脏论坛专家共识
该专家共识由肝脏论坛组织制定,针对代谢功能障碍相关脂肪性肝炎(MASH)临床试验中疑似药物性肝损伤(DILI)的因果关系评估,讨论了肝活检的合理使用。共识指出虽无特征性病理表现,但组织学评估可能改变患者管理、明确损伤模式和严重程度、识别支持DILI而非MASH进展的表现、识别预后特征、描述DILI临床病理表型,并界定影响试验终止和药物后续开发决策的病变。
要点
- MASH试验中疑似DILI的因果关系评估具有挑战性,肝活检并非常规用于该评估。
- 虽无特征性病理表现,组织学评估可能改变患者管理并明确损伤模式和严重程度。
- 组织学可识别支持DILI而非MASH进展的表现、预后特征及影响试验终止决策的病变。
核心结论
- 虽无特征性病理表现,MASH临床试验中疑似DILI的组织学评估可能改变患者管理、明确损伤模式和严重程度、识别支持DILI而非MASH进展的表现、识别预后特征、描述DILI临床病理表型,并界定影响试验终止和药物后续开发决策的病变。
研究设计与样本
- 2020年至2022年,肝脏论坛召开了一系列关于MASH试验中肝活检问题的网络研讨会,并成立组织学工作组以生成系列共识文件,本稿件聚焦于肝活检作为DILI因果关系评估的一部分。
主要发现
- 提供了关于肝活检在MASH药物临床试验中疑似DILI因果关系评估中作用的专家意见、指导和推荐。
- 回顾了既往MASH项目中的经验教训并识别了差距。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Causality assessment of suspected drug-induced liver injury (DILI) during metabolic dysfunction-associated steatohepatitis (MASH) clinical trials can be challenging, and liver biopsies are not routinely performed as part of this evaluation. While the field is moving away from liver biopsy as a diagnostic and prognostic tool, information not identified by non-invasive testing may be provided on histology. AIM: To address the appropriate utilisation of liver biopsy as part of DILI causality assessment in this setting. METHODS: From 2020 to 2022, the Liver Forum convened a series of webinars on issues pertaining to liver biopsy during MASH trials. The Histology Working Group was formed to generate a series of consensus documents addressing these challenges. This manuscript focuses on liver biopsy as part of DILI causality assessment. RESULTS: Expert opinion, guidance and recommendations on the role of liver biopsy as part of causality assessment of suspected DILI occurring during clinical trials for a drug(s) being developed for MASH are provided. Lessons learned from prior MASH programs are reviewed and gaps identified. CONCLUSIONS: Although there are no pathognomonic features, histologic evaluation of suspected DILI during MASH clinical trials may alter patient management, define the pattern and severity of injury, detect findings that favour a diagnosis of DILI versus MASH progression, identify prognostic features, characterise the clinicopathological phenotype of DILI, and/or define lesions that influence decisions about trial discontinuation and further development of the drug.
引用
- Palmer M, Kleiner DE, Goodman Z, et al. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Aliment Pharmacol Ther. 2023. PMID: 37877759. doi:10.1111/apt.17762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。